Annual report
4583.TEDINET S100QGF6
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥713m | 2021-01-01 → 2021-12-31 | Standalone | Net sales |
| Revenue | ¥481m | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥448m | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥213m | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | −¥1.3bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.4bn | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.5bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.4bn | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.5bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥2.3bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥3.5bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.8bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.8bn | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥446m | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.7bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2020-12-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2019-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.3bn | at 2018-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.1bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.5bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.7bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥35m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥4m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥26m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥271m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.9bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10m | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.74 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.06 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-44.61 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-57.26 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥36.7 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥45.55 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥77.99 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥78.1 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥98.89 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.6% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.5% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,781,500 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,505,200 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 33,283,500 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 26,781,500 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 49 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 49 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 42 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 38 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 37 | at 2018-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 21
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2022-12-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-12-31 | −¥472m |
| Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-12-31 | −¥1.1bn |
| Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥631m |
| Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥631m |
| Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥349m |
| —segment total | employees | at 2022-12-31 | 39 pure |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-12-31 | ¥631m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-12-31 | ¥631m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-12-31 | −¥787m |
| Reconciling Itemsreconciling | segment assets | at 2021-12-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-12-31 | −¥445m |
| Drug Discovery And Developmentreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥103m |
| Drug Discovery And Developmentreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥103m |
| Drug Discovery And Developmentreportable segment | segment profit | 2021-01-01 → 2021-12-31 | −¥1.2bn |
| Drug Discovery Supportreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥610m |
| Drug Discovery Supportreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥610m |
| Drug Discovery Supportreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥320m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-01-01 → 2021-12-31 | ¥713m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-01-01 → 2021-12-31 | ¥713m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-01-01 → 2021-12-31 | −¥890m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 834
| Item | Context | Value | Unit |
|---|---|---|---|
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E26096-000KikuchiMatsuoMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000KikuchiMatsuoMember | Original text (Japanese)（注）４ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000YamakawaYoshiyukiMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000YamakawaYoshiyukiMember | Original text (Japanese)山川 善之 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000YamakawaYoshiyukiMember | 1962-08-21 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E26096-000YamakawaYoshiyukiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000YamakawaYoshiyukiMember | Original text (Japanese)（注）５ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000SakamotoNiroMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000SakamotoNiroMember | Original text (Japanese)坂本 二朗 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000SakamotoNiroMember | 1960-11-05 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E26096-000SakamotoNiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E26096-000SakamotoNiroMember | Original text (Japanese)（注）６ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row8Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYearDuration | Original text (Japanese)当社は子会社がありませんので、連結財務諸表を作成しておりません。 | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Statement of income (text) | CurrentYearDuration | Text · Plus | |
| Detailed schedule of cost of sales (text) | CurrentYearDuration | Text · Plus | |
| Statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant_NonConsolidatedMember | Text · Plus | |
| Notes regarding inventories (text) | CurrentYearInstant_NonConsolidatedMember | Text · Plus | |
| Notes regarding research and development expenses text blok | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding other of selling general and administrative expenses (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration_NonConsolidatedMember | Text · Plus | |
| Notes leases financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities financial statements (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |